Malignant Pleural Mesothelioma| A Pipeline Analysis Report 2018| Technavio | Financial Buzz

Malignant Pleural Mesothelioma| A Pipeline Analysis Report 2018| Technavio

Technavio has announced their latest pipeline analysis report for malignant
pleural mesothelioma. The report comprises an in-depth analysis
of the pipeline molecules under investigation within the defined data
collection period to treat malignant pleural mesothelioma.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180622005569/en/

Technavio has published a new report on the drug development pipeline for malignant pleural mesothelioma, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the coming years.

This report is available at a USD 1,000 discount for a limited time
only: View
market snapshot before purchasing

Malignant pleural mesothelioma: Market overview

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer
that develops in a thin layer of tissue surrounding the lungs known as
the pleura. As per a research, MPM is the most common form of malignant
mesothelioma, accounting for 90%. The primary cause of MPM is the
inhalation of microscopic asbestos fibers. Once the person inhales
asbestos dust, the body struggles to eliminate the needle-like fibers of
asbestos from lungs.

According to a senior analyst at Technavio for research on
oncology, “The symptoms of MPM include dyspnea, persistent dry or
raspy cough, chest pain, difficulty swallowing also known as dysphagia,
and coughing up blood also known as hemoptysis. The incidence of MPM has
been increasing since the middle of the 20th century. There are marked
variations in the incidence of MPM within and between nations.”

Malignant pleural mesothelioma: Segmentation
analysis

This market research report segments the malignant pleural mesothelioma
market based on therapies employed (monotherapy and combination
therapy), RoA (IV, oral, intrapleural, intratumoral, subcutaneous,
intratumoral/ subcutaneous, and undisclosed), therapeutic modality
(monoclonal antibody, small molecule, biological, cell therapy,
oncolytic virus, recombinant fusion protein, and gene therapy), targets
for drugs under development (PD-1, tubulin, tyrosine kinase, PD-1/CTLA-4
inhibitor, arginine deaminase, stemness of CSC, CD13 receptor isoform,
CD26 antigen, CD8+T-cell, FAK, FGFs, interferon beta, megakaryocytic
potentiating factor, mesothelin, N2 position of guanine in DNA, TEA
domain, WT1, thymidine kinase, and undisclosed), MoA (PD-1 inhibitor,
immunostimulant, thymidine kinase expression stimulants, tubulin
polymerization inhibitor, tyrosine kinase inhibitor, WT1 inhibitor,
PD-1/CTLA-4 inhibitor, alkylating agent, arginine deaminase replacement,
stemness of CSC inhibitor, capillary permeability modulator, CD26
antigen inhibitor, FGF inhibitor, FAK inhibitor, interferon beat
stimulant, megakaryocytic potentiating factor inhibitor, mesothelin
inhibitor, YAP-TEAD inhibitor), and recruitment status (recruiting,
active not recruiting, completed, active, enrolling by invitation, and
undisclosed).

Monotherapy includes the use of a single drug to treat a disorder or a
disease. In the current pipeline, 15 molecules that are under
investigation are monotherapy.

IV delivers drugs directly into a vein. In the current pipeline, 16
molecules are administered by IV route.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005569/en/